Pulmonary Hypertension

Emerging Therapies for Interstitial Lung Disease - AJMC.com Managed Markets Network Emerging Therapies for Interstitial Lung Disease - AJMC.com Managed Markets Network Targeting CD146-HIF-1α Feedback Signals May Prevent PH Development, Study Suggests - Pulmonary Hypertension News Cystic fibrosis in children: Causes, symptoms, and treatment - Medical News Today Emerging Therapies for Interstitial Lung Disease - AJMC.com Managed Markets Network Posted: 19 Aug 2019 12:00 AM PDT Interstitial lung disease (ILD) encompasses a wide range of conditions and has significant direct and indirect costs for patients, insurance payers, and society. Although new drugs that reduce the progression of fibrosis have been developed for ILD with a progressive fibrotic phenotype, more work is needed to find therapies that abrogate the fibrotic process and treat patients with autoimmune-related ILD that does not respond to immunosuppressant drug...

Effects of Pulmonary Hypertension on Outcomes After MVR for Rheumatic Mitral Stenosis - The Cardiology Advisor Effects of Pulmonary Hypertension on Outcomes After MVR for Rheumatic Mitral Stenosis - The Cardiology Advisor Posted: 06 Aug 2019 12:00 AM PDT For patients with rheumatic mitral stenosis and pulmonary hypertension (PH) who undergo mitral valve replacement (MVR), proper control of systolic pulmonary arterial pressure (sPAP) and right ventricular systolic pressure (RVSP) may help prevent tricuspid regurgitation progression, according to study results published in the Annals of Thoracic Surgery . The aim of this retrospective study was to assess the effect of PH on long-term survival and late-onset tricuspid regurgitation in patients with rheumatic mitral stenosis who underwent a MVR. Patients were categorized into either a non-PH cohort with a sPAP ≤50 mm Hg or a PH cohort with a sPAP >50 mm Hg. Preoperative measurements of s...

Effects of Pulmonary Hypertension on Outcomes After MVR for Rheumatic Mitral Stenosis - The Cardiology Advisor Effects of Pulmonary Hypertension on Outcomes After MVR for Rheumatic Mitral Stenosis - The Cardiology Advisor Posted: 06 Aug 2019 12:00 AM PDT For patients with rheumatic mitral stenosis and pulmonary hypertension (PH) who undergo mitral valve replacement (MVR), proper control of systolic pulmonary arterial pressure (sPAP) and right ventricular systolic pressure (RVSP) may help prevent tricuspid regurgitation progression, according to study results published in the Annals of Thoracic Surgery . The aim of this retrospective study was to assess the effect of PH on long-term survival and late-onset tricuspid regurgitation in patients with rheumatic mitral stenosis who underwent a MVR. Patients were categorized into either a non-PH cohort with a sPAP ≤50 mm Hg or a PH cohort with a sPAP >50 mm Hg. Preoperative measurements of s...

New guidance on potentially fatal blood clots published today - European Society of Cardiology New guidance on potentially fatal blood clots published today - European Society of Cardiology Posted: 31 Aug 2019 12:06 AM PDT Paris, France – 31 Aug 2019: The European Society of Cardiology (ESC) Guidelines on acute pulmonary embolism are published online today in European Heart Journal (1), and on the ESC website. (2) They were developed in collaboration with the European Respiratory Society (ERS). Acute pulmonary embolism is the third most common cause of cardiovascular death in Europe, after heart attack and stroke, contributing to more than 350,000 deaths each year. A blood clot (thrombus) in a deep vein, usually in the legs, is dislodged and travels to the lungs where it blocks one or more vessels. This typically occurs if the vein wall is damaged, blood flow is too slow, or the blood becomes too thick. Major surgery such as knee or hip ...

ESC Provides New Acute Pulmonary Embolism Guideline - MD Magazine ESC Provides New Acute Pulmonary Embolism Guideline - MD Magazine Posted: 31 Aug 2019 06:07 AM PDT Stavros Konstantinides, MD, PhD A new, collaborative guideline for acute pulmonary embolism now provides step-by-step diagnostics for the third most common cause of cardiovascular death in Europe. The new guideline from the European Society of Cardiology (ESC) and European Respiratory Society (ERS)—presented at the ESC Congress 2019 on Saturday—provides clinicians a detailed process to proper diagnosis of the dislodged blood clot condition which results in approximately 350,000 deaths in Europe annually. It also provides updated insight into the capability of differing embolism screening methods, the duration of care necessary for hospitalized patients, and the therapeutic management of patients with pulmonary embolism and cancer or pregnancy. Acute pulmonary embolism...

Ensuring Appropriate Access to Pulmonary Arterial Hypertension Therapy - AJMC.com Managed Markets Network Ensuring Appropriate Access to Pulmonary Arterial Hypertension Therapy - AJMC.com Managed Markets Network Posted: 27 Jun 2019 12:00 AM PDT Kristin B. Highland, MD, MSCR; Kathleen E. Hughes, MBA; Kenneth J. Williams, MA, MBA; Brigit Kyei-Baffour, MBA; Samantha Ferguson Pulmonary arterial hypertension (PAH) is a progressive, complex disease. PAH is a type of pulmonary hypertension (PH) and can be further categorized into 7 subdivisions, representing a variety of causal and phenotypic factors. Patients with PH, including PAH, are typically fragile and experience multiple comorbidities; they therefore require individualized treatment plans based on their risk status and etiology. Based on a review of clinical evidence, a wide variety of treatment options exist for PAH, including general measures (eg, physical activity and oral anticoagulants),...

New guidance on potentially fatal blood clots published today - European Society of Cardiology New guidance on potentially fatal blood clots published today - European Society of Cardiology Posted: 31 Aug 2019 12:06 AM PDT Paris, France – 31 Aug 2019: The European Society of Cardiology (ESC) Guidelines on acute pulmonary embolism are published online today in European Heart Journal (1), and on the ESC website. (2) They were developed in collaboration with the European Respiratory Society (ERS). Acute pulmonary embolism is the third most common cause of cardiovascular death in Europe, after heart attack and stroke, contributing to more than 350,000 deaths each year. A blood clot (thrombus) in a deep vein, usually in the legs, is dislodged and travels to the lungs where it blocks one or more vessels. This typically occurs if the vein wall is damaged, blood flow is too slow, or the blood becomes too thick. Major surgery such as knee or hip ...